home / stock / auph / auph news


AUPH News and Press, Aurinia Pharmaceuticals Inc From 04/19/22

Stock Information

Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com

Menu

AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...

AUPH - Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis

– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals livi...

AUPH - Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings

Presentations include new analyses of AURORA 1 and details on the ENLIGHT-LN registry Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today an...

AUPH - Aurinia gains the most in three months on above average volume

The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals (AUPH +10.6%) have added more than a tenth on Wednesday to record the biggest intraday gain in over three months amid rising chatter on social media. Currently, about 3.8 million Aurinia (NASDAQ:AUPH) shares ...

AUPH - Aurinia Pharmaceuticals gains on report investors pushing for sale

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review. Aurinia holders, led by Switzerland-based MKT Tactical Fund, has written to the AUPH chairman, asking that the board to hire a bank...

AUPH - Despite Market Reaction, Aurinia Pharmaceuticals Is On Track And Ahead Of Schedule

Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently. I explore the reasons specific to Aurinia and then compare recent results to my valuation model. My model turns out to be very conservative and it still arrives at a target price of $75 for AUP...

AUPH - Aurinia extends losses as analysts cut price targets after Q4 results

The commercial-stage biotech, Aurinia Pharmaceuticals (AUPH -4.7%), is trading lower for the third straight session on Wednesday to reach a seven-month low after several Wall Street analysts trimmed their price targets on the stock citing the company’s lackluster Q4 2021 results. ...

AUPH - EVBG, IRNT and NTRB among mid-day movers

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

AUPH - Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2021 Results - Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2021 Earnings Conference Call February 28, 2022 08:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conf...

AUPH - IntriCon, NeuroSense top healthcare gainers; Aurinia, Lexicon lead losers' pack

Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...

AUPH - Aurinia falls after lower-than-expected sales outlook for 2022

Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022. Aurinia (AUPH), which commerci...

Previous 10 Next 10